Dr. Gollnick joined the faculty at RPCI in 1990 after postdoctoral training at DNAX Research Institute in Palo Alto, CA and serving as a staff scientist at ImmunLogic Pharmaceutical Corp. Dr. Gollnick has been funded by the National Cancer Institute for the past 17 years and is currently the PI as well as a Project Leader of a Program Project Grant continuously funded for the past 21 years.
Dr. Gollnick is an Associate Editor of Photochemistry and Photobiology and has served as a reviewer for numerous journals including Cancer Research, Journal of Immunology and Oncogene. Dr. Gollnick is also a member of the NCI Radiation Therapeutics and Biology Study Section and has reviewed grants for the US Army Research Program as well as the Canadian and Dutch Cancer Societies.
Dr. Gollnick served as Director of Graduate Studies for the Tumor Immunology Program for many years and is currently a member of the Graduate Studies Steering Committee. She was honored with the Excellence in Graduate Education Award in 2010.
Dr. Gollnick’s research focuses on the yin and yang of inflammation in the progression and treatment of cancer. Chronic inflammation contributes to the development and progression of many cancers, including prostate cancer. Dr. Gollnick’s laboratory explores how tumor cells co-opt the host immune system to promote chronic inflammation that leads to increased vascularization, suppression of anti-tumor immunity and increased tumor cell proliferation and migration. The goal of this work is to develop novel therapeutic targets based on increased understanding of the interaction of tumor cells and immune cells.
Unlike chronic inflammation, acute inflammation promotes the development of anti-tumor immunity. Many anti-cancer modalities, including radiation, chemotherapy and photodynamic therapy (PDT), result in acute inflammation. PDT is an FDA approved anti-cancer modality used for the elimination of early disease and palliation of late stage malignancies. Dr. Gollnick’s laboratory has shown that PDT stimulates anti-tumor immunity that is capable of combating distant disease. Her current focus is on developing clinical protocols for the treatment of head and neck and lung cancers with a goal of providing enhanced tumor control, including control of metastases, with minimal effect of quality of life.
Kabingu E, Oseroff AR, Wilding GE, Gollnick SO. Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin. Cancer Res., 15: 4460-4466, 2009
Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA and Gollnick SO. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4 dependent regulation of tumor vasculature. Cancer Res., 71:1637-1646, 2011
Riddell JR, Maier P, Sass SN, Moser MT, Foster BA. and Gollnick SO. Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α. PLoS One 7:e50394, 2012
Brackett CM, Muhitch JB, Evans SS, Gollnick SO. IL-17 promotes neutrophil entry into tumor draining lymph nodes following induction of sterile inflammation. J. Immunol. 191:4348-57, 2013
Shams M, Owczarczak B, Manderscheid-Kern P, Bellnier DA, and Gollnick SO, Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol. Immunother. 64:287-297, 2015